2023
Master transcription factor reprograming unleashes selective translation promoting castration resistance and immune evasion in lethal prostate cancer.
Santasusagna S, Zhu S, Jawalagatti V, Carceles-Cordon M, Ertel A, Garcia-Longarte S, Song W, Fujiwara N, Li P, Mendizabal I, Petrylak D, Kelly W, Reddy E, Wang L, Schiewer M, Lujambio A, Karnes J, Knudsen K, Cordon-Cardo C, Dong H, Huang H, Carracedo A, Hoshida Y, Rodriguez-Bravo V, Domingo-Domenech J. Master transcription factor reprograming unleashes selective translation promoting castration resistance and immune evasion in lethal prostate cancer. Cancer Discovery 2023, 13: 2584-2609. PMID: 37676710, PMCID: PMC10714140, DOI: 10.1158/2159-8290.cd-23-0306.Peer-Reviewed Original ResearchConceptsLethal prostate cancerProstate cancerCastration resistanceImmune evasionPharmacologic targetingAnti-PD-1 therapyMajor histocompatibility complex IDeprivation therapyMicrophthalmia transcription factorAndrogen receptorPreclinical modelsTherapeutic strategiesCancerTherapyDruggable mechanismMaster transcription factorTranscription factorsKey mRNAsSpecific mRNAsMRNAFactor 3bEvasionSelected ArticlesTargetingTumorsThe Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES
Armstrong A, Iguchi T, Azad A, Villers A, Alekseev B, Petrylak D, Szmulewitz R, Alcaraz A, Shore N, Holzbeierlein J, Gomez-Veiga F, Rosbrook B, Zohren F, Haas G, Gourgiotti G, El-Chaar N, Stenzl A. The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES. European Urology 2023, 84: 229-241. PMID: 37179240, DOI: 10.1016/j.eururo.2023.04.002.Peer-Reviewed Original ResearchMeSH KeywordsAndrogen AntagonistsAndrogensDisease-Free SurvivalHumansMaleProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantTreatment OutcomeConceptsHormone-sensitive prostate cancerAndrogen deprivation therapyRadiographic progression-free survivalMetastatic hormone-sensitive prostate cancerOligometastatic hormone-sensitive prostate cancerOverall survivalProstate cancerDeprivation therapyHazard ratioAndrogen receptor inhibitionEarly treatment intensificationEfficacy of enzalutamideRisk of undertreatmentSystemic treatment strategiesSecondary efficacy endpointsPhase 3 studyProgression-free survivalNumber of metastasesConfidence intervalsProportional hazards modelPost Hoc AnalysisEfficacy endpointOligometastatic diseaseSecondary endpointsTreatment intensification
2022
Effect of Androgen–Androgen Receptor Directed Therapy on COVID-19 Outcome in Prostate Cancer Patients
Ünlü S, Shin J, Par-Young J, Simonov M, Vinetz J, Petrylak D, Kang I, Kim J. Effect of Androgen–Androgen Receptor Directed Therapy on COVID-19 Outcome in Prostate Cancer Patients. Cancer Investigation 2022, 41: 77-83. PMID: 36373994, DOI: 10.1080/07357907.2022.2139839.Peer-Reviewed Original ResearchMeSH KeywordsAndrogensCOVID-19HumansMaleProstatic NeoplasmsReceptors, AndrogenRetrospective StudiesSARS-CoV-2ConceptsProstate cancer patientsCOVID-19 outcomesCancer patientsPoor COVID-19 outcomesAndrogen-androgen receptorExpression of TMPRSS2COVID-19 infectionSARS-CoV-2Directed therapyMean hospitalizationPCa patientsHospitalization ratesPCa casesRetrospective analysisOutcome differencesPatientsDefinitive conclusionsStatistical significanceData generate hypothesesHospitalizationTherapyTMPRSS2Cellular entryOutcomesARDT
2006
Quality of Life and Pain in Advanced Stage Prostate Cancer: Results of a Southwest Oncology Group Randomized Trial Comparing Docetaxel and Estramustine to Mitoxantrone and Prednisone
Berry D, Moinpour C, Jiang C, Ankerst D, Petrylak D, Vinson L, Lara P, Jones S, Taplin M, Burch P, Hussain M, Crawford E. Quality of Life and Pain in Advanced Stage Prostate Cancer: Results of a Southwest Oncology Group Randomized Trial Comparing Docetaxel and Estramustine to Mitoxantrone and Prednisone. Journal Of Clinical Oncology 2006, 24: 2828-2835. PMID: 16782921, DOI: 10.1200/jco.2005.04.8207.Peer-Reviewed Original ResearchConceptsPain palliationMP armProstate cancerMcGill Pain Questionnaire-Short FormPrimary patient-reported outcomesPain Questionnaire-Short FormPresent Pain Intensity scaleAndrogen-independent prostate cancerAdvanced stage prostate cancerProstate cancer moduleMedian overall survivalLife Questionnaire C30Cancer Core QualityPatient-reported outcomesSuperior clinical efficacyDisease-related symptomsStage prostate cancerPain intensity scaleQuality of lifeRandom assignmentQuestionnaire-Short FormBone painDE armAnalgesic useEligible patients
2000
Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients
Lee N, Fawaaz R, Olsson C, Benson M, Petrylak D, Schiff P, Bagiella E, Singh A, Ennis R. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. International Journal Of Radiation Oncology • Biology • Physics 2000, 48: 1443-1446. PMID: 11121646, DOI: 10.1016/s0360-3016(00)00785-9.Peer-Reviewed Original ResearchConceptsProstate-specific antigenPositive bone scanRadionuclide bone scanBone scanClinical stageLow-risk groupGleason scorePositive BSIndependent predictorsProstate cancerNegative bone scanSignificant independent predictorsProstate cancer patientsSame risk groupProstate cancer biopsiesPathologic reviewStaging evaluationConsecutive patientsGleason 2Cancer patientsVs. 0Odds ratioRisk groupsPatientsCancer biopsiesColitis and docetaxel-based chemotherapy
Kreis W, Petrylak D, Savarese D, Budman D. Colitis and docetaxel-based chemotherapy. The Lancet 2000, 355: 2164. PMID: 10902651, DOI: 10.1016/s0140-6736(05)72789-6.Peer-Reviewed Original ResearchDEXAMETHASONE DOES NOT SIGNIFICANTLY CONTRIBUTE TO THE RESPONSE RATE OF DOCETAXEL AND ESTRAMUSTINE IN ANDROGEN INDEPENDENT PROSTATE CANCER
WEITZMAN A, SHELTON G, ZUECH N, OWEN C, JUDGE T, BENSON M, SAWCZUK I, KATZ A, OLSSON C, BAGIELLA E, PFAFF C, NEWHOUSE J, PETRYLAK D. DEXAMETHASONE DOES NOT SIGNIFICANTLY CONTRIBUTE TO THE RESPONSE RATE OF DOCETAXEL AND ESTRAMUSTINE IN ANDROGEN INDEPENDENT PROSTATE CANCER. Journal Of Urology 2000, 163: 834-837. PMID: 10687988, DOI: 10.1016/s0022-5347(05)67815-9.Peer-Reviewed Original ResearchConceptsProstate-specific antigenAndrogen-independent prostate cancerIndependent prostate cancerResponse rateMedian timeProstate cancerBaseline prostate-specific antigenSerum prostate-specific antigenMedian PSA increasePSA response rateDexamethasone monotherapyEstramustine administrationPSA declineMedian durationPartial responsePSA increaseDisease 3Day 1Specific antigenWeek 9Day 2EstramustinePatientsDocetaxelDexamethasoneAndrogen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study.
Hussain M, Fisher E, Petrylak D, O’Connor J, Wood D, Small E, Eisenberger M, Crawford E. Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A Southwest Oncology Group Study. Journal Of Clinical Oncology 2000, 18: 1043-9. PMID: 10694555, DOI: 10.1200/jco.2000.18.5.1043.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerAndrogen deprivationProstate cancerTreatment interruptionGrade 3Southwest Oncology Group studyCombination of suraminTherapy-related deathsGrade 4 toxicityCooperative group settingTreatment of patientsNumber of patientsFeasibility of treatmentAdequate hematologicOverall survivalCoagulation parametersDisease progressionSuramin treatmentPatientsSecond courseTreatment cyclesMultiple coursesCancerSuraminSuch treatment
1999
Chemotherapy for advanced hormone refractory prostate cancer
Petrylak D. Chemotherapy for advanced hormone refractory prostate cancer. Urology 1999, 54: 30-35. PMID: 10606282, DOI: 10.1016/s0090-4295(99)00452-5.Peer-Reviewed Original ResearchConceptsHormone-refractory prostate cancerRefractory prostate cancerProstate-specific antigenProstate cancerBone painAdvanced hormone-refractory prostate cancerHormone-resistant prostate cancerSerum prostate-specific antigenCombination of estramustinePhase III studySoft tissue metastasesTaxane-based therapyCombination of mitoxantroneMetastatic prostate cancerDrug Administration approvalCorticosteroid therapyHormone therapyIII studyTissue metastasesRandomized trialsTreatment optionsHistorical controlsAdministration approvalClinical practiceUS FoodDocetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
Hussain M, Petrylak D, Fisher E, Tangen C, Crawford D. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. Seminars In Oncology 1999, 26: 55-60. PMID: 10604271.Peer-Reviewed Original ResearchConceptsHormone-refractory prostate cancerProstate cancerHormone-refractory prostate cancer patientsProstate-specific antigen levelRandomized phase III trialEnd pointPrimary end pointSecondary end pointsPhase III trialsSingle institution experienceSide effect profileSouthwest Oncology GroupCombination of mitoxantroneProstate cancer patientsStandard armIII trialsOncology GroupAssessment of qualityClinical outcomesEffect profileRandomized trialsTreatment armsAntigen levelsInstitution experienceCancer patientsWhich patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients
Lee N, Newhouse J, Olsson C, Benson M, Petrylak D, Schiff P, Bagiella E, Malyszko B, Ennis R. Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients. Urology 1999, 54: 490-494. PMID: 10475360, DOI: 10.1016/s0090-4295(99)00150-8.Peer-Reviewed Original ResearchConceptsPositive CT scanGleason scoreComputed tomography scanCT scanClinical stageProstate cancerIndependent predictorsTomography scanSerum prostate-specific antigen levelProstate-specific antigen levelClinical stage T2bLow-risk patientsBiopsy Gleason scoreGleason score 8Negative CT scanAbdominopelvic CT scansGleason score 2Low-risk groupSignificant independent predictorsProstate cancer biopsiesStage T2bPathologic reviewStaging evaluationPositive CTAntigen levelsPhase I trial of docetaxel with estramustine in androgen-independent prostate cancer.
Petrylak D, Macarthur R, O'Connor J, Shelton G, Judge T, Balog J, Pfaff C, Bagiella E, Heitjan D, Fine R, Zuech N, Sawczuk I, Benson M, Olsson C. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. Journal Of Clinical Oncology 1999, 17: 958-67. PMID: 10071290, DOI: 10.1200/jco.1999.17.3.958.Peer-Reviewed Original ResearchConceptsAndrogen-independent prostate cancerEPT patientsProstate cancerMPT patientsProgressive metastatic androgen-independent prostate cancerMetastatic androgen-independent prostate cancerDose-limiting myelosuppressionGrade 3/4 granulocytopeniaPSA response ratePhase II doseDoses of docetaxelPhase I trialPharmacokinetics of docetaxelBone painMeasurable diseaseOral estramustinePo tidPain medicationPartial responseSerum PSAI trialNarcotic analgesicsTime of entryPatientsDay 1
1996
Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy
Wright G, Grob B, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer P, Moriarty R. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996, 48: 326-334. PMID: 8753752, DOI: 10.1016/s0090-4295(96)00184-7.Peer-Reviewed Original ResearchConceptsProstate-specific membrane antigenAndrogen deprivation therapyExpression of PSMAProstate cancerLNCaP cellsAndrogen deprivationMetastatic specimensMembrane antigenCombination androgen deprivation therapyProstate-specific antigen expressionTissue specimensAntigen-positive tumor cellsHormone-independent prostate cancerPost-treatment specimenAndrogen deprivation treatmentAbsence of androgenPresence of testosteroneExtent of stainingWestern blot analysisAndrogen treatmentPSA expressionMetastatic tissuesPSMA expressionAntigen expressionProstate carcinoma
1995
Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms.
Scher H, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, Mendelsohn J, Cordon-Cardo C. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clinical Cancer Research 1995, 1: 545-50. PMID: 9816014.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorTGF-alpha expressionTGF-alphaGrowth factor alphaGrowth factor receptorFactor alphaPattern of expressionEpithelial cellsProstate cancer cell growthAutocrine/paracrine interactionsStaining patternRole of EGFRAndrogen-independent tumorsFactor receptorUntreated primary tumorsMalignant prostate epithelial cellsAndrogen-independent diseaseImmunohistochemical staining patternHomogeneous staining patternProstate cancer progressionMalignant epithelial cellsPrimary prostate tumorsCancer cell growthAndrogen-independent conditionGrowth factor pathways
1993
Cytotoxic chemotherapy for advanced hormone‐resistant prostate cancer
Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone‐resistant prostate cancer. Cancer 1993, 71: 1098-1109. PMID: 7679039, DOI: 10.1002/1097-0142(19930201)71:3+<1098::aid-cncr2820711432>3.0.co;2-g.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntineoplastic AgentsBone NeoplasmsCisplatinClinical Trials as TopicCoumarinsDoxorubicinDrug Administration ScheduleDrug ResistanceFluorouracilHumansIntercalating AgentsMaleMethotrexateNeoplasm StagingPolyaminesProstate-Specific AntigenProstatic NeoplasmsRemission InductionSomatostatinConceptsDrug trialsAdvanced hormone-resistant prostate cancerHormone-resistant prostate cancerObjective response rateCombination of vinblastineMost cytotoxic agentsReliable disease markersNew drug trialsProstate cancer cellsCurrent reviewNew therapeutic agentsPartial remissionVisceral metastasesAdvanced adenocarcinomaCytotoxic chemotherapyObjective responseContinuous infusionNonresponsive tumorsMarginal efficacyHormonal manipulationProstate cancerNew agentsResponse rateCytotoxic drugsTherapeutic agents
1992
Estramustine and Vinblastine: Use of Prostate Specific Antigen as a Clinical Trial End Point for Hormone Refractory Prostatic Cancer
Seidman A, Scher H, Petrylak D, Dershaw D, Curley T. Estramustine and Vinblastine: Use of Prostate Specific Antigen as a Clinical Trial End Point for Hormone Refractory Prostatic Cancer. Journal Of Urology 1992, 147: 931-934. PMID: 1371564, DOI: 10.1016/s0022-5347(17)37426-8.Peer-Reviewed Original ResearchConceptsHormone-refractory prostatic cancerProstatic cancerProgressive hormone-refractory prostate cancerElevated prostate-specific antigen levelsProstate-specific antigen levelHormone-refractory prostate cancerClinical trial end pointsOutpatient treatment regimenRefractory prostate cancerSpecific antigen levelsTrial end pointsProstate-specific antigenManageable toxicityMedian durationPartial responsePSA levelsTreatment regimenEstramustine phosphateAntigen levelsProstate cancerAdditive cytotoxicityMedian decreasePatientsSpecific antigenHuman prostate